Easy to use kits measuring real-time energy flux, substrate utilization and mitochondrial function in living cells, without the need for expensive analysers.
Advanced high throughput disease models and assays for early prediction of drug toxicity, mitochondrial liability and mechanistic characterisation.
Measure and monitor oxygen throughout the cell culture workflow. Multiplex assays for intracellular / extracellular oxygen concentration and ROS.
Get in Touch
To Register Interest or Order ProductsMake Enquiry
NEW PUBLICATION The FASEB Journal 31st July
A PP2A-mediated feedback mechanism controls Ca2+-dependent NO synthesis under physiological oxygen
Although critical for life, oxygen is an inherently toxic molecule with a plethora of damaging effects on our bodies. To combat this, our bodies are designed to control delivery of oxygen to our tissues and maintain a steep gradient between the atmosphere and cells. Despite this, cells grown in the laboratory are routinely maintained at atmospheric oxygen levels (~21% oxygen), which is approximately 4 times higher than the cells would experience in our body. To investigate this, we have grown cells from human blood vessels (endothelium) at more physiologically relevant oxygen levels (5% oxygen) and compared them with equivalent cells cultured under atmospheric oxygen levels.
Glycolysis a Central Player in Disease Progression
Recent research across a diversity of fields is fuelling a renewed interest in glycolytic flux measurements, as glycolysis is highlighted again and again as a central player in disease progression and related metabolic adaptation. This is particularly true in areas such as Cancer, Hypoxia, Diabetes, Stem Cell biology and Immunometabolism. Glycolytic activity can be conveniently assessed by measuring lactate-derived acidification and, using the pH-Xtra™ Glycolysis Assay, this is now possible on conventional fluorescence plate readers. Combined with NEW pH-Xtra™ Stress Test, researchers now have the tools to conveniently and comprehensively characterise both basal glycolysis and glycolytic capacity, while avoiding the need for expensive dedicated instrumentation and complicated corrections for CO2 derived acidification.
Luxcel Biosciences Ltd Announce Further EU H2020 Success with €1.5million Award and Rapid Expansion Plans
Luxcel Biosciences Ltd is delighted to announce a further European H2020 funding award, supporting the €1.5million MetaTox-HS product development, under the highly prestigious SME Instrument (SMEInst-02-2016-2017). Drug failure and high development cost (est. €2.3bn/new drug) has driven enormous growth in market need for in vitro scientific tests and models of disease that better replicate drug effect in the patient (in vivo). Critical tests are either not available, or only available on a few large, expensive dedicated instruments.
MetaCell, Cell Metabolism Made Easy
Led by Luxcel Biosciences, the consortium of Axiogenesis AG, BMG LABTECH GmbH and Luxcel supported by leading academic institutes Oxford University UK and Imperial College London are actively demonstrating a Gold Standard platform, comprising cell assays, disease models and services, together with high performance metabolism tests designed for use on laboratory standard instrumentation – the multi-mode microtiter plate reader.
This project funded by the EU H2020 Fast Track to Innovation initiative is called, MetaCell-TM, metabolism analysis made easy for Cell Translational Medicine.